Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (α(IIb)β3) inhibitors

Blood

Volumn 92, Issue 9, 1998, Pages 3240-3249

  Peter, Karlheinz ^a   Schwarz, Meike ^b   Ylänne, Jari ^b   Kohler, Benedikt ^b   Moser, Martin ^b   Nordt, Thomas ^b   Salbach, Peter ^b   Kübier, Wolfgang ^b   Bode, Christoph ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINO ACID DERIVATIVE; DISINTEGRIN; FIBRINOGEN RECEPTOR ANTAGONIST; INDOMETACIN; MONOCLONAL ANTIBODY 2G 12; MONOCLONAL ANTIBODY P2; MONOCLONAL ANTIBODY PAC 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; HUMAN; LIGAND BINDING; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0032212143     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.9.3240.421k21_3240_3249     Document Type: Article

References (39)

1. Roth JG, Calverly DC: Aspirin, platelets, and thrombosis: Theory and practice. Blood 83:885, 1994
2. Lefkovits J, Plow EF, Topol E: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 23:1553, 1995
3. Coller BS: Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 100:57, 1997 (suppl)
4. Tscheng JE: Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 78:35, 1996
5. Coller BS: GPIIb/IIIa antagonists: Pathophysiology and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 78:730, 1997
6. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11, 1992
7. Calvete JJ: Clues for understanding the structure and function of a prototypic human integrin: The platelet GP IIb/IIIa complex. Thromb Haemost 72:1, 1993
8. Ylänne J, Chen Y, O'Toole TE, Loftus JC, Takada Y, Ginsberg MH: Distinct functions of integrin alpha and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesions. J Cell Biol 122:223, 1993
9. Plow EF, Pierschbacher MB, Ruoslathi E, Marguerie GA, Ginsberg MH: The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 82:8057, 1985
10. Frelinger AL III, Lam SCT, Plow EF, Smith MA, Loftus JC, Ginsberg MH: Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 263:12397, 1988
11. Frelinger AL III, Cohen I, Plow EF, Smith MA, Roberts J, Lam SCT, Ginsberg MH: Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 265:6346, 1990
12. Parise LV, Helgerson SL, Steiner B, Nannizzi L, Phillips DR: Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb/IIIa. J Biol Chem 262:12597, 1987
13. 3 (platelet GP IIb-IIIa). Cell 65:409, 1991
14. Nakatani S, Hato T, Minamoto Y, Fujita S: Differential inhibition of fibrinogen binding to agonist- and RGDS peptide-activated states of GPIIb-IIIa by an anti-GPIIIa monoclonal antibody, PMA5. Thromb Haemost 76:1030, 1996
15. 2 (LFA-1, CD11a/CD18) cytoplasmic domain/cytoskeleton interaction. J Exp Med 181:315, 1995
16. O'Toole TE, Katagiri Y, Faull RJ, Peter K, Tamuara R, Quaranta V, Loftus JC, Shattil SJ, Ginsberg MH: Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol 124:104, 1994
17. 3 integrin (platelet GP IIb-IIIa) is an intrinsic property of the receptor. Cell Regul 1:883, 1990
18. Shattil SJ, Hoxie JA, Cunningham M, Brass LF: Changes in glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem 260:11107, 1985
19. 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem 266:6346, 1991
20. Müller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J : Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation 96:1130, 1997
21. Taub R, Gould RJ, Garsky VM, Ciccarone TM, Hoxie J, Friedman PA, Shattil SJ: A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. J Biol Chem 264:259, 1989
22. Calvete JJ, Schafer W, Soszka T, Lu WQ, Cook JJ, Jameson BA, Niewiarowski S: Identification of the disulfide bond pattern in albolabrin, an RGD-containing peptide from the venom of Trimeresurus albolabris for the expression of platelet aggregation inhibitory activity. Biochemistry 30:5225, 1991
23. Savage B, Marcec UM, Chao BH, Harker LA, Maraganone JM, Ruggeri ZM: Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb/IIIa complex inhibits receptor function. J Biol Chem 265:11766, 1990
24. Coller BS: Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol 103:451, 1986
25. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE: Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 88:907, 1996
26. Tscheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman DS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin Fab 7E3 in high-risk angioplasty. Circulation 90:1757, 1994
27. Coller B: A new murine monoclonal antibody reports an activation-dependent change in the conformation of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 76:101, 1985
28. Tomiyama Y, Tsubakio T, Piotrowicz RS, Kurata Y, Loftus JC, Kunicki TJ: The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on non-activated platelets is accessible to high-affinity macromolecules. Blood 79:2303, 1992
29. IIb. Science 254:845, 1991
30. 3 subunit: Differential effects on cell spreading, recruitment to adhesion plaques, endocytosis, and phagocytosis. J Biol Chem 270:9550, 1995
31. Huttenlocher A, Ginsberg MH, Horwitz AF: Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol 134:1551, 1996
32. Wu C, Keivens VM, O'Toole TE, McDonald JA, Ginsberg MH: Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Cell 83:715, 1995
33. Clark EA, Brugge JS: Integrins and signal transduction pathways: The road taken. Science 268:233, 1995
34. Christopoulos C, Mackie I, Lahiri A, Machin S: Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 4:729, 1993
35. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM: Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 91:2882, 1995
36. Vorchheimer DA, Fuster V: Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety. Circulation 97:312, 1998
37. Marcinkiewicz C, Rosenthal LA, Mosser DM, Kunicki TJ, Niewiarowski S: Immunological characterization of eristostatin and echistatin binding sites on alpha lib beta 3 and alpha V beta 3 integrins. Biochem J 317:817, 1996
38. Satoh T, Kouns WC, Yamshita Y, Kamiyama T, Steiner B: Tetrafibricin, a novel non-peptide fibrinogen receptor antagonist, induces conformational changes in glycoprotein IIb/IIIa. Biochem J 301:785, 1994
39. Cox D, Acki T, Seki J, Motoyama Y, Yoshida K: Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. Thromb Haemost 75:503, 1996